향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2033개
향후 6개월 catalyst 4건 · 타깃·모달리티 분포
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 7월 | Kadcyla (ado-trastuzumab emtansine / T-DM1)ADC · HER2 | Phase 2 | Recruiting | Clearance of ctDNA with the addition of neratinib to trastuzumab-DM1 in patients with MRD detectable by the RaDaR assay, following standard neoadjuvant therapy, surgery, and initiation of T-DM1 | 보통 | NCT05388149 |
| 2026년 7월 | Enhertu (trastuzumab deruxtecan)ADC · HER2 | Phase 2 | Not yet recruiting | Intracranial objective response rate(IC-ORR) | 보통 | NCT06088056 |
| 2026년 7월 | Kadcyla (ado-trastuzumab emtansine / T-DM1)ADC · HER2 | Phase 1 | Active, not recruiting | Incidence of dose limiting toxicities in Phase 1a monotherapy; Incidence of adverse events in Phase 1a monotherapy; incidence of laboratory abnormalities in Phase 1a monotherapy; incidence of ECG abnormalities in Phase 1a monotherapy; incidence of dose limiting toxicities in Phase 1a combination with fam-trastuzumab deruxtecan (T-DXd); Incidence of adverse events in Phase 1a combination with T-DXd; incidence of laboratory abnormalities in Phase 1a combination with T-DXd; incidence of ECG abnormalities in Phase 1a combination with T-DXd; incidence of dose limiting toxicities in Phase 1a combination with trastuzumab emantasine (T-DM1); Incidence of adverse events in Phase 1a combination with T-DM1; incidence of laboratory abnormalities in Phase 1a combination with T-DM1; incidence of ECG abnormalities in Phase 1a combination with T-DM1; Incidence of adverse events in Phase 1b monotherapy; incidence of laboratory abnormalities in Phase 1b monotherapy; incidence of ECG abnormalities in Phase 1b monotherapy | 신뢰 높음 | NCT05650879 |
| 2026년 7월 | Enhertu (trastuzumab deruxtecan)ADC · HER2 | Phase 1 | Active, not recruiting | Incidence of dose limiting toxicities in Phase 1a monotherapy; Incidence of adverse events in Phase 1a monotherapy; incidence of laboratory abnormalities in Phase 1a monotherapy; incidence of ECG abnormalities in Phase 1a monotherapy; incidence of dose limiting toxicities in Phase 1a combination with fam-trastuzumab deruxtecan (T-DXd); Incidence of adverse events in Phase 1a combination with T-DXd; incidence of laboratory abnormalities in Phase 1a combination with T-DXd; incidence of ECG abnormalities in Phase 1a combination with T-DXd; incidence of dose limiting toxicities in Phase 1a combination with trastuzumab emantasine (T-DM1); Incidence of adverse events in Phase 1a combination with T-DM1; incidence of laboratory abnormalities in Phase 1a combination with T-DM1; incidence of ECG abnormalities in Phase 1a combination with T-DM1; Incidence of adverse events in Phase 1b monotherapy; incidence of laboratory abnormalities in Phase 1b monotherapy; incidence of ECG abnormalities in Phase 1b monotherapy | 신뢰 높음 | NCT05650879 |
향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2033개
향후 6개월 catalyst 4건 · 타깃·모달리티 분포
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 7월 | Kadcyla (ado-trastuzumab emtansine / T-DM1)ADC · HER2 | Phase 2 | Recruiting | Clearance of ctDNA with the addition of neratinib to trastuzumab-DM1 in patients with MRD detectable by the RaDaR assay, following standard neoadjuvant therapy, surgery, and initiation of T-DM1 | 보통 | NCT05388149 |
| 2026년 7월 | Enhertu (trastuzumab deruxtecan)ADC · HER2 | Phase 2 | Not yet recruiting | Intracranial objective response rate(IC-ORR) | 보통 | NCT06088056 |
| 2026년 7월 | Kadcyla (ado-trastuzumab emtansine / T-DM1)ADC · HER2 | Phase 1 | Active, not recruiting | Incidence of dose limiting toxicities in Phase 1a monotherapy; Incidence of adverse events in Phase 1a monotherapy; incidence of laboratory abnormalities in Phase 1a monotherapy; incidence of ECG abnormalities in Phase 1a monotherapy; incidence of dose limiting toxicities in Phase 1a combination with fam-trastuzumab deruxtecan (T-DXd); Incidence of adverse events in Phase 1a combination with T-DXd; incidence of laboratory abnormalities in Phase 1a combination with T-DXd; incidence of ECG abnormalities in Phase 1a combination with T-DXd; incidence of dose limiting toxicities in Phase 1a combination with trastuzumab emantasine (T-DM1); Incidence of adverse events in Phase 1a combination with T-DM1; incidence of laboratory abnormalities in Phase 1a combination with T-DM1; incidence of ECG abnormalities in Phase 1a combination with T-DM1; Incidence of adverse events in Phase 1b monotherapy; incidence of laboratory abnormalities in Phase 1b monotherapy; incidence of ECG abnormalities in Phase 1b monotherapy | 신뢰 높음 | NCT05650879 |
| 2026년 7월 | Enhertu (trastuzumab deruxtecan)ADC · HER2 | Phase 1 | Active, not recruiting | Incidence of dose limiting toxicities in Phase 1a monotherapy; Incidence of adverse events in Phase 1a monotherapy; incidence of laboratory abnormalities in Phase 1a monotherapy; incidence of ECG abnormalities in Phase 1a monotherapy; incidence of dose limiting toxicities in Phase 1a combination with fam-trastuzumab deruxtecan (T-DXd); Incidence of adverse events in Phase 1a combination with T-DXd; incidence of laboratory abnormalities in Phase 1a combination with T-DXd; incidence of ECG abnormalities in Phase 1a combination with T-DXd; incidence of dose limiting toxicities in Phase 1a combination with trastuzumab emantasine (T-DM1); Incidence of adverse events in Phase 1a combination with T-DM1; incidence of laboratory abnormalities in Phase 1a combination with T-DM1; incidence of ECG abnormalities in Phase 1a combination with T-DM1; Incidence of adverse events in Phase 1b monotherapy; incidence of laboratory abnormalities in Phase 1b monotherapy; incidence of ECG abnormalities in Phase 1b monotherapy | 신뢰 높음 | NCT05650879 |